Improved downstream process for the production of plasmid DNA for gene therapy

• Autorzy: Urthaler J. , Buchinger W. , Necina R.
• Języki publikacji: EN

Abstrakty

EN

Gene therapy and genetic vaccines promise to revolutionize the treatment of inherited and acquired diseases. Since viral vectors are generally associated with numerous disadvantages when applied to humans, the administration of naked DNA, or DNA packed into lipo- or polyplexes emerge as viable alternatives. To satisfy the increasing demand for pharmaceutical grade plasmids we developed a novel economic downstream process which overcomes the bottlenecks of common lab-scale techniques and meets all regulatory requirements. After cell lysis by an in-house developed gentle, automated continuous system the sequence of hydrophobic interaction, anion exchange and size exclusion chromatography guarantees the separation of impurities as well as undesired plasmid isoforms. After the consecutive chromatography steps, adjustment of concentration and final filtration are carried out. The final process was proven to be generally applicable and can be used from early clinical phases to market-supply. It is scaleable and free of animal-derived substances, detergents (except lysis) and organic solvents. The process delivers high-purity plasmid DNA of homogeneities up to 98% supercoiled form at a high yield in any desired final buffer.

Słowa kluczowe

EN

gene therapy; production; physicochemical property; chromatography; purification; plasmid DNA; industrial scale

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2005
• Tom: 52
• Numer: 3
• Opis fizyczny: p.703-711,fig.,ref.

Twórcy

autor

Urthaler J.

autor

Buchinger W.

autor

Necina R.

Bibliografia

• Asenjo JA, Andrews BA (1990) Enzymatic cell lysis for product release. Bioprocess Technol 9: 143–175.
• Bencina M, Podgornik A, Strancar A (2004) Characterization of methacrylate monoliths for purification of DNA molecules. J Sep Sci 27: 801–810.
• Birnboim HC, Doly J (1979) A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res 7: 1513–1523.
• Birnboim HC (1983) A rapid alkaline extraction method for the isolation of plasmid DNA. Methods Enzymol 100: 243–255.
• Branovic K, Forcic D, Ivancic J, Strancar A, Barut M, Gulija TK, Zgorelec R, Mazuran R (2004) Application of short monolithic columns for fast purification of plasmid DNA. J Chromatogr B 801: 331–337.
• Carlson A, Signs M, Liermann L (1995) Mechanical disruption of Escherichia coli for plasmid recovery. Biotechnol Bioeng 48: 303–315.
• Diogo MM, Queiroz JA, Monteiro GA, Martins SA, Ferreira GN, Prazeres DM (2000) Purification of a cystis fibrosis plasmid vector for gene therapy using hydrophobic interaction chromatography. Biotechnol Bioeng 68: 576–783.
• Diogo MM, Queiroz JA, Monteiro GA, Martins SAM, Ferreira GNM, Prazeres DMF (2000) Purification of a cystic fibrosis plasmid vector for gene therapy using hydrophobic interaction chromatography. Biotechnol Bioeng 68: 576–583.
• Endres HN, Johnson JA, Ross CA, Welp JK, Etzel MR (2003) Evaluation of an ion-exchange membrane for the purification of plasmid DNA. Biotechnol Appl Biochem 37: 259–266.
• Eon-Duval A (2003) Large-scale manufacturing of plasmid DNA for gene therapy and DNA vaccination – Part 1: The suitability of current techniques to purify plasmid without adding RNase. BioPharm August: 48–57.
• Eon-Duval A, Burke G (2004) Purification of pharmaceutical- grade plasmid DNA by anion-exchange chromatography in an RNase-free process. J Chromatogr B 804: 327–335.
• Ferreira GNM, Monteiro GA, Prazeres DMF, Cabral JMS (2000) Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications. Trends Biotechnol 18: 380–388.
• Foster D (1992) Cell disruption: breaking up is hard to do. Biotechnology (NY) 10: 1539–1541.
• Giovannini R, Freitag R, Tennikova TB (1998) High-performance membrane chromatography of supercoiled plasmid DNA. Anal Chem 70: 3348–3354.
• Giovannini R, Freitag R´(2002) Continuous isolation of plasmid DNA by annular chromatography. Biotechnol Bioeng 77: 445–454.
• Gustavsson PE, Lemmens R, Nyhammar T, Busson P, Larsson PO (2004) Purification of plasmid DNA with a new type of anion-exchange beads having a non-charged surface. J Chromatogr A 1038: 131–140.
• Hayashizaki Y (1997) EP Patent 0814156.
• Horn NA, Meek JA, Budahazi G, Marquet M (1995) Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum Gene Ther 6: 565–573.
• Horn N, Budahazi G, Marquet M (1998) WO Patent 98/05767.
• Jansen J-C, Petterson T (1993) Large scale chromatography of proteins. In Preparative and Production Scale Chromatography. Ganetsos G, Barker PE, eds, pp 559–590. Marcel Dekker, New York.
• Kreuzer KN, Cozzarelli NR (1980) Formation and resolution of DNA catenanes by DNA gyrase. Cell 20: 245–254.
• Lander RJ, Winters M, Meacle F (2001) WO Patent 01/46215.
• Levy MS, Ciccolini LAS, Yim SS, Tsai JT, Titchener-Hooker N, Shamlou PA, Dunnill P (1999a) The effects of material properties and fluid flow intensity on plasmid DNA recovery during cell lysis. Chem Eng Sci 54: 3171–3178.
• Levy MS, Collins IJ, Yim SS, Ward JM, Titchener-Hooker N, Shamlou PA, Dunnill P (1999b) Effect of shear on plasmid DNA in solution. Bioprocess Biosyst Eng 20: 7–13.
• Levy MS, Lotfian P, O`Kennedy R, Lo-Yim MY, Shamlou PA (2000a) Quantitation of supercoiled circular content in plasmid DNA solutions using a fluorescence-based method. Nucleic Acids Res 28: E57.
• Levy MS, O’Kennedy RD, Shamlou PA, Dunnhill P (2000b) Biochemical engineering approaches to the challenges of producing pure plasmid DNA. Trends Biotechnol 18: 296–305.
• Marquet M, Horn N, Meek J, Budahazi G (1995) WO Patent 95/21250.
• Mao QM, Johnston A, Prince IG, Hearn MTW (1991) Predicting the performance of non-porous particles in affinity chromatography. J. Chromatogr A 548: 147–163.
• Mao QM, Stockmann R, Prince IG, Hearn MT (1993) Highperformance liquid chromatography of amino acids, peptides and proteins. CXXVI. Modelling of protein adsorption with non-porous and porous particles in a finite bath. J Chromatogr A 646: 67–80.
• Marquet M, Horn NA, Meek JA (1997) Characterization of plasmid DNA vectors for use in human gene therapy. BioPharm May: 42–50.
• Martin R (1996) Gel Electrophoresis: Nucleic Acids. Bios Scientific, London.
• McNeilly D (1999) WO Patent 99/29832.
• Middaugh CR, Evans RK, Mongomery DL, Casimiro DR (1998) Analysis of plasmid DNA from a pharmaceutical perspective. J Pharm Sci 87: 130–146.
• Miller H (1987) Practical aspects of preparing phage and plasmid DNA: Growth, maintenance, and storage of bacteria and bacteriophage. Methods Enzymol 152: 145– 170.
• Murphy JC, Jewell DL, White KI, Fox GE, Willson RC (2003) Nucleic acid separations utilizing immobilized metal affinity chromatography. Biotechnol Prog 19: 982–986.
• Necina R, Urthaler J, Strancar A, Jancar J, Merhar M, Barut M, Podgornik A (2003) WO Patent 03/051483.
• Podgornik A, Barut M, Strancar A, Josic D (1999) WO Patent 99/44053.
• Prather KJ, Sagar S, Murphy J, Chartrain M (2003) Industrial scale production of plasmid DNA for vaccine and gene therapy: Plasmid design, production and purification. Enzyme Microb Technol 33: 865–883.
• Prazeres DM, Schluep T, Cooney C (1998) Preparative purification of supercoiled plasmid DNA using anion-exchange chromatography. J Chromatogr A 806: 31–45.
• Prazeres DMF, Ferreira GNM, Monteiro GA, Cooney CL, Cabral JMS (1999) Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecks. Trends Biotechnol 17: 169–174.
• Ribeiro SC, Monteiro GA, Cabral JM, Prazeres DM (2002) Isolation of plasmid DNA from cell lysates by aqueous two-phase systems. Biotechnol Bioeng 78: 376–384.
• Schleef M (1999) Issues of large scale plasmid DNA manufacturing. In Biotechnology, 2nd edn vol 5a. Recombinant Proteins, Monoclonal Antibodies and Therapeutic Genes. Rehm HJ, Reed G, Pühler A, Stadler P, eds, pp 443–469. Wiley-VCH , Weinheim.
• Schluep T, Cooney CL (1998) Purification of plasmids by triplex affinity interaction. Nucleic Acids Res 26: 4524–4528.
• Shamlou PA (2003) Scaleable processes for the manufacture of therapeutic quantities of plasmid DNA. Biotechnol Appl Biochem 37: 207–218.
• Sinden RR, Alkek AB (1994) DNA Structure and Function. pp 95–133. Academic Press, San Diego.
• Sofer G, Hagel L (1997a) Escherichia coli, The purification strategy, Chromatography. In Handbook of Process Chromatography, A Guide to Optimization, Scale-up, and Validation, pp 10–12, 43–54, 132–172. Academic Press, London.
• Sofer G, Hagel L (1997a) Optimization goals. In Handbook of Process Chromatography, A Guide to Optimization, Scaleup, and Validation, pp 54–58. Academic Press, London.
• Strancar A, Podgornik A, Barut M, Necina R (2002) Short monolithic columns as stationary phases for biochromatography. In Advances in Biochemical Engineering/Biotechnology, vol 76, Scheper T, ed, pp 49–85. Springer Verlag, Berlin.
• Strick TR, Allemand J-F, Bensimon D, Croquette V (1998) Behavior of supercoiled DNA. Biophys J 74: 2016–2028.
• Summers DK (1996) The Biology of Plasmids. Blackwell Science, Oxford.
• Svec F, Frechet JMJ (1995) Modified poly(glycidyl methacrylate- co-ethylene dimethacrylate) continuous rod columns for preparative-scale ion-exchange chromatography of proteins. J Chromatogr A 702: 89–95.
• Tennikova TB, Svec F (1993) High performance membrane chromatography: highly efficient separation method for proteins in ion-exchange, hydrophobic interaction and reversed-phase modes. J Chromatogr A 646: 279–288.
• US FDA (1996a) Points to Consider on Plasmid DNA Vaccines for Preventive Invectious Disease Indications, US Food and Drug Administration, Rockville, MD.
• US FDA (1996b) Addendum to The Points to Consider in Human Somatic Cell and Gene Therapy, US Food and Drug Administration, Rockville, MD.
• US FDA (1996c) Addendum to The Points to Consider in Human Somatic Cell and Gene Therapy. Hum Gene Ther 7: 1181–1190.
• US FDA (1998) Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy, US Food and Drug Administration, Rockville, MD.
• Urthaler J, Necina R, Ascher C, Wöhrer H (2004) WO Patent 2004/085643.
• Urthaler J, Schlegl R, Podgornik A, Strancar A, Jungbauer A, Necina R (2005) Application of monoliths for plasmid DNA purification–development and transfer to production. J Chromatogr A 1065: 93–106.
• Weir N (1999) Non-viral vectors for gene therapy. In Biotechology, Mountain A, Ney UM, Schomburg D, eds, vol 5a, pp 427–441. Wiley-VCH, Weinheim.
• Wicks IP, Howell ML, Hancock T (1995) Bacterial lipopolysaccharide copurifies with plasmid DNA: implications for animal models and human gene therapy. Hum Gene Ther 6: 317–323.
• Varley DL, Hitchcock AG, Weiss AM, Horler WA, Cowell R, Peddie L, Sharpe GS, Thatcher DR, Hanak JA (1999) Production of plasmid DNA for human gene therapy using modified alkaline cell lysis and expanded bed anion exchange chromatography. Bioseparation 8: 209–217.
• Zhang S, Krivosheyeva A, Nochumson S (2003) Largesscale capture and partial purification of plasmid DNA using anion-exchange membrane capsules. Biotechnol Appl Biochem 37: 245–249.
• Zöchling A, Hahn R, Ahrer K, Urthaler J, Jungbauer A (2004) Mass transfer characteristics of plasmids in monoliths. J Sep Sci: 27: 819–827.